Bortezomib (PS-341, Velcade) is a novel, first-in-class proteasomeinhibitor with antitumor activity against a number of hematologic andnonhematologic malignancies.
Terri Davidson, PharmD
Advertisement
Articles by Terri Davidson, PharmD
Advertisement
Latest Updated Articles
- Pharmacology, Pharmacokinetics, and Practical Applications of Bortezomib
Published: December 1st 2004 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
3
3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer
4
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
5
